UNSPSC 51453402: Niridazole

This classification denotes an antiprotozoal agent with the molecular formula C6H6N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N116U8Y5QQ, chemically known as 2-imidazolidinone, 1-(5-nitro-2-thiazolyl)- but generally known as niridazole, which bears US NIH Compound Identifier 6093. European Medicines Agency schedules Niridazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09304MIG.

UNSPSC 51453402 Niridazole is a Commodity code that captures pharmaceutical products acquired by state and local health agencies, though the recent opportunities block shows little activity directly tied to this specific agent. The two recent records posted under this code involve different pharmaceutical acquisitions: the Illinois Department of Public Health's award to Chartwell Rx LLC for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through the MMCAP Infuse cooperative purchasing vehicle, and Seminole County, Florida's IFB for naloxone and drug deactivation systems for community health support. State and local health departments and county health authorities are the primary issuing bodies for pharmaceutical procurements at this tier, typically sourcing through cooperative purchasing consortiums or competitive bidding to manage inventory for emergency preparedness, disease treatment, and harm-reduction programs.

Activity under the code appears concentrated in Florida and Illinois based on the recent postings. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract over 12 months with two renewal options to Chartwell Rx LLC via Bid Number 26-482DPH-PREPD-B-53392, posted August 28, 2026, with an initial response date of September 11, 2026; this was a completed award through an Invitation for Bid process with no set-asides identified. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though the posted deadline (July 26, 2023) appears to be a historical record date rather than current opportunity. Both solicitations required vendor compliance with drug-free workplace certification, E-Verify, and insurance requirements; the Seminole County procurement noted potential FEMA funding with attendant federal compliance obligations.